We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Scaling Non-Viral Cell Therapy Approaches for Solid Tumor Treatments

Scaling Non-Viral Cell Therapy Approaches for Solid Tumor Treatments content piece image

Hear from today’s cell therapy manufacturing leaders about scaling non-viral cell therapy approaches for solid tumor treatments and what that means for your manufacturing process.

In this webinar, speakers from PACT Pharma Inc. and Thermo Fisher Scientific discuss how modular instrumentation platforms can enable automation and standardization of the end-to-end manufacturing workflow, from cell isolation and activation to genetic modification and expansion.

Watch now to learn more about: 

  • Scaling and automating the cell therapy manufacturing process
  • The safety and regulatory advantages of non-viral transfection for cell therapy
  • A highly efficient non-viral precision genome engineering process to manufacture personalized cell therapies for solid tumors
Nektaria Andronikou
Nektaria Andronikou
Senior R&D Manager
Thermo Fisher Scientific
Kyle Jacoby, Ph.D.
Kyle Jacoby, Ph.D.
Senior Director of Gene Editing
Evan Zynda, Ph.D.
Evan Zynda, Ph.D.
Senior Staff Scientist, Cell Biology